Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oncocyte Corp (OCX)

Oncocyte Corp (OCX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,647
  • Shares Outstanding, K 8,273
  • Annual Sales, $ 1,500 K
  • Annual Income, $ -27,780 K
  • 60-Month Beta 1.00
  • Price/Sales 27.32
  • Price/Cash Flow N/A
  • Price/Book 1.81
Trade OCX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +175,363.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.82 +8.35%
on 09/30/24
3.34 -8.68%
on 09/20/24
-0.05 (-1.61%)
since 09/11/24
3-Month
2.80 +8.93%
on 08/05/24
3.48 -12.35%
on 07/15/24
-0.10 (-3.17%)
since 07/11/24
52-Week
2.08 +46.63%
on 11/08/23
4.34 -29.72%
on 11/21/23
-0.10 (-3.17%)
since 10/11/23

Most Recent Stories

More News
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

OCX : 3.05 (-1.61%)
OncoCyte: Q2 Earnings Snapshot

OncoCyte: Q2 Earnings Snapshot

OCX : 3.05 (-1.61%)
S&P Futures Tick Lower as Investors Digest Big Bank Earnings

June S&P 500 E-Mini futures (ESM24) are down -0.12% this morning as market participants geared up for earnings from big U.S. banks.

ESM24 : 5,471.89s (-0.09%)
JPM : 222.29 (+4.44%)
WFC : 60.99 (+5.61%)
C : 65.74 (+3.56%)
PARA : 10.35 (+0.10%)
AAPL : 227.55 (-0.65%)
TEAM : 187.06 (+1.66%)
FAST : 76.82 (+9.76%)
VAR1.D.DX : 5.050 (+4.77%)
AMD : 167.89 (+2.26%)
INTC : 23.56 (+1.46%)
OCX : 3.05 (-1.61%)
Oncocyte Corporation to Present at the LD Micro Invitational XIII

Irvine, California--(Newsfile Corp. - June 1, 2023) - Oncocyte Corporation (NASDAQ: OCX) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard...

OCX : 3.05 (-1.61%)
Oncocyte to Participate at Upcoming Investor Conferences

IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient...

OCX : 3.05 (-1.61%)
Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022

IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient...

OCX : 3.05 (-1.61%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating OncoCyte Corporation for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

OCX : 3.05 (-1.61%)
Oncocyte to Announce Second Quarter 2022 Financial Results

IRVINE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient...

OCX : 3.05 (-1.61%)
Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice

IRVINE, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), is a precision diagnostics company with the mission to improve...

OCX : 3.05 (-1.61%)
Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test’s Potential to Expand the Clinical Use of Immunotherapy

DetermaIO identifies responders to immunotherapy among the 95% of patients with colon cancer currently ineligible for treatment based on existing...

OCX : 3.05 (-1.61%)

Business Summary

OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.

See More

Key Turning Points

3rd Resistance Point 3.31
2nd Resistance Point 3.23
1st Resistance Point 3.14
Last Price 3.05
1st Support Level 2.97
2nd Support Level 2.89
3rd Support Level 2.80

See More

52-Week High 4.34
Fibonacci 61.8% 3.48
Fibonacci 50% 3.21
Last Price 3.05
Fibonacci 38.2% 2.94
52-Week Low 2.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar